0000000000614605

AUTHOR

Fausto Baldanti

showing 7 related works from this author

Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH sur…

2017

Background Scant information is available about how transplant centers are managing their use of quantitative molecular testing (QNAT) assays for active cytomegalovirus (CMV) infection monitoring in solid organ transplant (SOT) recipients. The current study was aimed at gathering information on current practices in the management of CMV infection across European centers in the era of molecular testing assays. Methods A questionnaire-based cross-sectional survey study was conducted by the European Study Group of Infections in Immunocompromised Hosts (ESGICH) of the Society of Clinical Microbiology and Infectious Diseases (ESCMID). The invitation and a weekly reminder with a personal link to …

0301 basic medicinecytomegalovirus; solid organ transplantation; survey.cytomegalovirus ; solid organ transplantation ; surveyCross-sectional studyCytomegalovirusTransplantsPractice Patterns030230 surgeryOrgan transplantationlaw.invention0302 clinical medicinePostoperative Complicationslaw03.02. Klinikai orvostanViralPractice Patterns Physicians'solid organ transplantationPolymerase chain reactionViral LoadEuropeInfectious DiseasesCytomegalovirus InfectionsPractice Guidelines as Topiccytomegalovirus; solid organ transplantation; survey; Antibiotic Prophylaxis; Antiviral Agents; Cross-Sectional Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA Viral; Europe; Guideline Adherence; Health Care Surveys; Humans; Immunocompromised Host; Immunosuppression; Organ Transplantation; Postoperative Complications; Practice Guidelines as Topic; Practice Patterns Physicians'; Real-Time Polymerase Chain Reaction; Transplant Recipients; Transplants; Viral LoadGuideline Adherencecytomegalovirus; solid organ transplantation; survey; Antibiotic Prophylaxis; Antiviral Agents; Cross-Sectional Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA Viral; Europe; Guideline Adherence; Health Care Surveys; Humans; Immunocompromised Host; Immunosuppression; Organ Transplantation; Postoperative Complications; Practice Guidelines as Topic; Practice Patterns Physicians'; Real-Time Polymerase Chain Reaction; Transplant Recipients; Transplants; Viral Load; Transplantation; Infectious Diseasesmedicine.medical_specialty030106 microbiologyCongenital cytomegalovirus infectionReal-Time Polymerase Chain ReactionAntiviral Agents03 medical and health sciencesImmunocompromised HostmedicineHumanssurveyIntensive care medicineImmunosuppression TherapyTransplantationPhysicians'business.industryDNAOrgan TransplantationAntibiotic Prophylaxismedicine.diseaseMolecular diagnosticsTransplant RecipientsCytomegalovirus infectionTransplantationcytomegalovirus; solid organ transplantation; survey; Transplantation; Infectious DiseasesCross-Sectional StudiesCytomegalovirus; Solid organ transplantation; Survey; Transplantation; Infectious DiseasesHealth Care SurveysDNA ViralImmunologySolid organ transplantationbusinessImmunosuppression
researchProduct

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

2021

Background & Aims There are limited data on patients with chronic HCV infection in whom combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus, we aimed to assess treatment failure and rescue treatment options in these patients. Methods Samples from 40 patients with HCV genotypes (GT) 1-4 in whom VOX/VEL/SOF retreatment failed were collected within the European Resistance Study Group. Population-based resistance analyses were conducted and clinical parameters and retreatment efficacies were evaluated retrospectively in 22 patients. Results Most VOX/VEL/SOF failure patients were infected with HCV GT3a (n = 18, 45%) or GT1a (n = 11, 28%) and had cirrhosis …

0301 basic medicineHepatitis C Virusmedicine.medical_specialtySofosbuvirVoxilaprevirPopulationresistance-associated substitutionsDirect-acting antiviralVoxilaprevir/velpatasvir/sofosbuvir.GastroenterologySettore MED/07Telaprevir03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVoxilaprevir/Velpatasvir/SofosbuvirInternal medicineBoceprevirRescue therapymedicineResistance-associated substitutioneducationdirect-acting antiviralsDAAeducation.field_of_studyHepatologybusiness.industryvirus diseasesGlecaprevirDAA; HCV; Hepatitis C Virus; Voxilaprevir/Velpatasvir/Sofosbuvir; direct-acting antivirals; rescue therapy; resistance-associated substitutionsdigestive system diseasesPibrentasvirRegimen030104 developmental biologychemistryHCV030211 gastroenterology & hepatologyHepatitis C virubusinessmedicine.drugJournal of Hepatology
researchProduct

Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

2017

0301 basic medicinemedicine.medical_specialtyhepacivirusHCV RASTreatment outcomeDrug ResistanceHCV genotypesDrug resistanceBiologyNS5A03 medical and health sciences0302 clinical medicineSecond linedrug resistance viral; humans; retreatment; treatment outcome; antiviral agents; hepacivirus; hepatitis c chronicInternal medicineDrug Resistance Viral; Humans; Retreatment; Treatment Outcome; Antiviral Agents; Hepacivirus; Hepatitis C ChronicDrug Resistance Viralantiviral agentsmedicineViralChronicNS5AhumansHepatologyhepatitis c chronicHepatitis CHepatitis C ChronicSettore MED/07 - Microbiologia e Microbiologia Clinicamedicine.diseaseHepatitis CVirologyHepatology HCV NS5A030104 developmental biologyHCVtreatment outcome030211 gastroenterology & hepatologyretreatmentdrug resistance viral
researchProduct

Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoie…

2004

Transplantation Centers using human cytomegalovirus (HCMV) antigenemia-based preemptive therapy will need to replace in the near future the antigenemia assay with a more standardized and automatable assay, such as a molecular assay quantifying HCMV DNA in blood (DNAemia). Thus, in view of replacing antigenemia with clinically safe cutoff values, DNAemia levels corresponding to antigenemia cutoffs guiding HCMV preemptive therapy were determined retrospectively in solid organ and hematopoietic stem cell transplant recipients (HSCTR) using an "in-house" quantitative PCR (QPCR) method. Since preemptive therapy had prevented appearance of HCMV disease in all patients tested, DNA cutoffs determin…

Human cytomegalovirusmedicine.medical_specialtymedicine.medical_treatmentCytomegalovirusHematopoietic stem cell transplantationAntiviral AgentsPolymerase Chain ReactionOrgan transplantationPostoperative ComplicationsPredictive Value of TestsBetaherpesvirinaeVirologyPositive predicative valuemedicineHumansCutoffViremiaAntigens ViralRetrospective StudiesAntiviral Agentbiologybusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesCytomegaloviruOrgan Transplantationbiology.organism_classificationmedicine.diseaseVirologyTransplantationInfectious DiseasesPredictive value of testsCytomegalovirus InfectionsDNA Viralbusiness
researchProduct

Recommendations for enterovirus diagnostics and characterisation within and beyond Europe

2018

Enteroviruses (EV) can cause severe neurological and respiratory infections, and occasionally lead to devastating outbreaks as previously demonstrated with EV-A71 and EV-D68 in Europe. However, these infections are still often underdiagnosed and EV typing data is not currently collected at European level. In order to improve EV diagnostics, collate data on severe EV infections and monitor the circulation of EV types, we have established European non-polio enterovirus network (ENPEN). First task of this cross-border network has been to ensure prompt and adequate diagnosis of these infections in Europe, and hence we present recommendations for non-polio EV detection and typing based on the co…

0301 basic medicineEuropean levelRECOMBINATIONNeurological infectionReviewMOUTH-DISEASEmedicine.disease_causeEMERGENCEFecesCentral Nervous System Infections[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesMedicineRespiratory Tract InfectionsCLINICAL SPECIMENSDiagnosticsDiagnostic Techniques and ProceduresComputingMilieux_MISCELLANEOUSEnterovirusEnterovirus D Human3. Good healthEuropeDetectionPCRInfectious DiseasesINFECTIONS[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesRNA ViralRNA INTERNAL CONTROLVp1 capsid proteinVirus isolation[SDV.MP.PRO] Life Sciences [q-bio]/Microbiology and Parasitology/Protistology[SDV.MP.PRO]Life Sciences [q-bio]/Microbiology and Parasitology/ProtistologyVirus03 medical and health sciencesVirologySURVEILLANCEEnterovirus InfectionsJournal ArticleRESPIRATORY VIRUSESddc:610TypingDisease burdenbusiness.industryOutbreakAMPLIFICATIONVirology[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyEnterovirus A Human030104 developmental biologyEnterovirusCapsid Proteins[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology610 Medizin und GesundheitEV typingbusinessEuropean non-polio enterovirus network (ENPEN)Journal of Clinical Virology
researchProduct

Measles in Italy: Viral strains and crossing borders

2019

In 2017, Italy experienced one of the largest outbreaks of measles in recent years, with 5404 notified cases and 4347 confirmed cases. A further 2029 cases were notified during the first 6 months of 2018, and 1516 of them were laboratory-confirmed. The B3 and D8 genotypes were identified as those responsible for the outbreak. Possible transmission routes can be established by monitoring the circulating measles virus strains in support of the national health authorities to warn people and travellers. Keywords: Outbreak, Measles, Genotype identification, Surveillance

0301 basic medicineGenotyping TechniquesWHO/EuropeSettore MED/42 - Igiene Generale E ApplicataDisease OutbreaksWHO0302 clinical medicineMeasleGenotype030212 general & internal medicineTravelSurveillancebiologyTransmission (medicine)General MedicineEmigration and ImmigrationInfectious DiseasesGenotype identificationItalyWorld Health Organization European RegionSequence AnalysisMicrobiology (medical)medicine.medical_specialtyGenotype030106 microbiologyWorld Health OrganizationMeasleslcsh:Infectious and parasitic diseasesEuropean Regional Verification Commission for Measles and Rubella Elimination; Genotype identification; MeaNS; Measles; Measles Nucleotide Surveillance; Outbreak; RVC; Surveillance; WHO; WHO/Europe; World Health Organization; World Health Organization European RegionOutbreak Measles Genotype identification SurveillanceMeasles virus03 medical and health sciencesGenotype identification; Measles; Outbreak; Surveillance; Emigration and Immigration; Genotype; Genotyping Techniques; Humans; Italy; Measles; Measles virus; Sequence Analysis DNA; Travel; Disease OutbreaksmedicineHumanslcsh:RC109-216Genotyping TechniquesMeaNSNational healthEuropean Regional Verification Commission for Measles and Rubella EliminationPublic healthOutbreakOutbreakSequence Analysis DNADNAmedicine.diseasebiology.organism_classificationVirologyRVCMeasles virusMeasles Nucleotide SurveillanceMeasles
researchProduct

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

2018

AbstractNatural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort of patients infected with the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed in 1445 HCV-infected DAA-naïve patients. Sanger-sequencing was performed by home-made protocols on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a and 99 GT4d samples. Overall, 20.7% (301/1455) of patients showed natural RASs, and the prevalence of multiclass-resistance was 7.3% (29/372 patients analysed). NS3-RASs were particularly common in GT1a and GT1b (45.2-10.8%, respectively), mai…

Male0301 basic medicineSofosbuvirHepacivirusDrug Resistancelcsh:MedicineHepacivirusViral Nonstructural Proteinsmedicine.disease_causeGastroenterologyHepatitis C Virus; HCV resistance-testchemistry.chemical_compound0302 clinical medicineGenotypePrevalenceVirallcsh:ScienceHCV resistance-testMultidisciplinarybiologyHepatitis CMiddle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCohortHCVFemale030211 gastroenterology & hepatologymedicine.drugAdultmedicine.medical_specialtyHepatitis C VirusGenotypeHCV RASHepatitis C virus03 medical and health sciencesInternal medicineDrug Resistance ViralmedicineHumansAdult; Aged; Drug Resistance Viral; Female; Hepacivirus; Hepatitis C; Humans; Italy; Male; Middle Aged; Prevalence; Viral Nonstructural Proteins; GenotypeNS5ANS5BAgedbusiness.industrylcsh:RHepatitis C Virus HCV resistance-testbiology.organism_classificationmedicine.disease030104 developmental biologychemistrylcsh:Qbusiness
researchProduct